

Datasheet



Mouse mAb to **Human IgA**
Clone **EBS-huA**
Isotype **IgG1-κ**

Source

A BALB/c mouse was immunized with human salivary proteins.
Fusion partner: SP-2/0.

Specifications

EBS-huA recognizes the third constant domain (CH3) of the alpha chain of human IgA and reacts with both IgA1 and IgA2 isotypes and not with other types of immunoglobulins. IgA type antibodies are secreted by B-cells associated with mucosal epithelia and therefore indicate malignancy if found in lymphoid infiltrates at other locations. Detection of IgA antibodies to EBV in serum may indicate nasopharyngeal carcinoma. Rising IgA anti EBV levels are associated with progression of disease.




Figure 1: Human colon stained for IgA (paraffin)

Species reactivity

Positive: human.

Applications

EBS-huA detects IgA in frozen and paraffin embedded tissue sections. It can be applied for typing of myeloma proteins in immunoprecipitation and is further suitable for immunoblotting, immunofluorescence and ELISA (quantification of IgA). EBS-huA can also be used as basis for anti-human IgA conjugates.

ELISA	Flow cytometry	Frozen sections	Immunoprecipitation	Paraffin sections	Western blot
+	+	+	+	Citrate	+

Format

Produced in tissue culture, contains no host Ig. Antibodies are affinity purified and presented in PBS with 0,02 % sodium azide.

Stored at 4°C- 8°C, shelf life is at least 24 months after purchase.

Dilution advice

- ELISA (solid phase: 0,1-100 µg/ml; tracer: 0,001-100 µg/ml for 30 min at RT).
- Flow cytometry (0.5-1.0 µg/million cells in 0.1 ml).
- Immunoblotting (1-2 µg/ml).
- Immunohistology (1-2 µg/ml for 30 min at RT; staining of formalin-fixed tissues is served by boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes).
- Immunoprecipitation (1-2 µg per 100-500 µg of total cell lysate protein/1 ml of anti mouse coated Sepharose-4B suspension).

Positive control

Human mucosal membranes, saliva.

Datasheet



References

- Biewenga J. et al, *Mol. Immunol.* **23**: 761-767 (1986).
Biewenga J. et al, *Adv. Exp. Med. Biol.* **216B**: 1239-1249 (1987).
Mestecky J. et al, *J. Immunol. Meth.* **193**: 103-148 (1996).
Oortwijn B.D. et al, *Mol Immunol.* **44(5)**:966-73 (2007).